PRC2 is a histone methyltransferase complex composed of EZH2, SUZ12 and EED.8,9 Moreover, 3-deazaneplanocin A (DZNep), an inhibitor targeting PRC2, could inhibit the activity of S-adenosyl-L-homocysteine hydrolase.10 DZNep inhibits tumour characteristics,11,12 and its synergistic interaction with gemcitabine enhances tumour regulatory effects.13 However, the specific mechanisms underlying the metastatic regulation of HOTAIR in PCa are largely unclear. The gene discussed is EZH2; the disease is neoplasm.